We are live on
!
Find out more
MC
Muhlenkamp & Co Portfolio holdings
AUM
$380M
1-Year Est. Return
43.74%
This Fund
S&P 500
This Quarter
Est. Return
+2.55%
1 Year Est. Return
+43.74%
3 Year Est. Return
+121.38%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$262M
AUM Growth
-$13.6M
(-4.9%)
Cap. Flow
-$15.5M
Cap. Flow
% of AUM
-5.91%
Top 10 Holdings %
Top 10 Hldgs %
49.65%
Holding
38
New
1
Increased
1
Reduced
8
Closed
1
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$6.07M |
| 2 |
Pfizer
PFE
|
+$8.85K |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
+$11.3M |
| 2 |
Gilead Sciences
GILD
|
+$6.08M |
| 3 |
ON Semiconductor
ON
|
+$4.18M |
| 4 |
DuPont de Nemours
DD
|
+$4.35K |
| 5 |
ESRX
Express Scripts Holding Company
ESRX
|
+$3.6K |
Sector Composition
| 1 | Healthcare | 25.81% |
| 2 | Technology | 23.38% |
| 3 | Consumer Discretionary | 12.41% |
| 4 | Financials | 8.53% |
| 5 | Materials | 7.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apple
AAPL
$4.89T
| $16.8M | 6.41% |
363,296
| – | – |
|
2
Bread Financial
BFH
$3.97B
| $16.4M | 6.27% |
88,360
-13
| -0% | -$2.22K |
|
3
Microsoft
MSFT
$2.98T
| $16.1M | 6.13% |
162,821
| – | – |
|
4
UnitedHealth
UNH
$384B
| $14.3M | 5.48% |
58,491
| – | – |
|
|
5
ON Semiconductor
ON
$34.3B
| $11.9M | 4.55% |
536,518
-172,948
| -24% | -$4.18M |
|
6
Celanese
CE
$5.02B
| $11.2M | 4.29% |
101,277
| – | – |
|
7
Rush Enterprises Class A
RUSHA
$6.19B
| $10.9M | 4.17% |
567,027
| – | – |
|
8
SPDR Gold Trust
GLD
$130B
| $10M | 3.82% |
84,371
| – | – |
|
|
ESRX
9
DELISTED
Express Scripts Holding Company
ESRX
| $10M | 3.82% |
129,511
-48
| -0% | -$3.6K |
|
10
Cameco
CCJ
$38B
| $9.76M | 3.72% |
867,482
| – | – |
|
|
11
Gilead Sciences
GILD
$169B
| $9.65M | 3.68% |
136,224
-86,153
| -39% | -$6.08M |
|
12
McKesson
MCK
$98.5B
| $9.48M | 3.62% |
71,090
| – | – |
|
13
Microchip Technology
MCHP
$44.4B
| $9M | 3.43% |
197,936
| – | – |
|
|
14
DuPont de Nemours
DD
$18.1B
| $7.7M | 2.94% |
46,119
-26
| -0.1% | -$4.35K |
|
15
Cognizant
CTSH
$21.1B
| $7.47M | 2.85% |
94,534
| – | – |
|
16
Biogen
BIIB
$30.8B
| $7.31M | 2.79% |
25,171
| – | – |
|
17
AutoZone
AZO
$50B
| $7.27M | 2.77% |
10,835
| – | – |
|
|
18
Jazz Pharmaceuticals
JAZZ
$15.2B
| $6.4M | 2.44% |
+37,155
| New | +$6.07M |
|
19
Pultegroup
PHM
$24.6B
| $5.92M | 2.26% |
205,951
| – | – |
|
20
Federated Hermes
FHI
$4.53B
| $5.92M | 2.26% |
253,785
| – | – |
|
|
CELG
21
DELISTED
Celgene Corp
CELG
| $5.76M | 2.2% |
72,493
| – | – |
|
22
Delta Air Lines
DAL
$57B
| $5.71M | 2.18% |
115,308
-55
| -0% | -$2.93K |
|
23
Thor Industries
THO
$4.03B
| $4.36M | 1.66% |
44,793
| – | – |
|
|
GMLP
24
DELISTED
Golar LNG Partners LP
GMLP
| $3.91M | 1.49% |
253,035
| – | – |
|
25
GameStop
GME
$9.84B
| $3.8M | 1.45% |
1,043,012
| – | – |
|
Similar funds
AC
MW
EAM
RWA
CSWG
BP
NICM
KFS
Muhlenkamp & Co's Q2 2018 Portfolio in Review
As of Q2 2018, Muhlenkamp & Co held 38 positions worth $262M, down 4.9% from $276M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Muhlenkamp & Co withdrew a net $15.5M in Q2 2018, closing 1 position and reducing 8 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $11.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 28% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Muhlenkamp & Co opened a new position in Jazz Pharmaceuticals worth $6.4M.
- Muhlenkamp & Co's largest Q2 2018 buy was Jazz Pharmaceuticals: 37,155 shares worth $6.4M.
- Muhlenkamp & Co added most to Pfizer in Q2 2018, an estimated $8.85K increase.
- Muhlenkamp & Co's biggest Q2 2018 reduction was Gilead Sciences, cutting an estimated $6.08M.
- Muhlenkamp & Co fully exited Bristol-Myers Squibb in Q2 2018, selling an estimated $11.3M.
- Muhlenkamp & Co's ten largest holdings make up 50% of its $262M portfolio in Q2 2018.
- Muhlenkamp & Co opened 1 new position and closed 1 in Q2 2018.
- Muhlenkamp & Co's portfolio value fell 4.9% quarter-over-quarter to $262M.
Based on Muhlenkamp & Co's 13F filing for Q2 2018, filed 13 Aug 2018.